Opioid agonist treatment take-home doses (‘carries’): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?

Opioid agonist treatment (OAT) is the primary intervention for opioid use disorder (OUD) in Canada and the USA. Yet, a number of barriers contribute to sub-optimal treatment uptake and retention, including daily-supervised medication administration. Thus, clients are eventually granted access to tak...

Descripción completa

Detalles Bibliográficos
Autores principales: Russell, Cayley, Lange, Shannon, Kouyoumdjian, Fiona, Butler, Amanda, Ali, Farihah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363267/
https://www.ncbi.nlm.nih.gov/pubmed/35948961
http://dx.doi.org/10.1186/s12954-022-00671-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363267/
https://www.ncbi.nlm.nih.gov/pubmed/35948961
http://dx.doi.org/10.1186/s12954-022-00671-z

Ejemplares similares